Close Menu

NEW YORK – Adaptive Biotechnologies announced Wednesday that Medicare contractor Palmetto has expanded coverage for Adaptive's ClonoSeq assay to include minimal residual disease monitoring in patients with chronic lymphocytic leukemia (CLL.) The expansion adds to existing coverage for B cell acute lymphoblastic leukemia and multiple myeloma, which was established in January 2019. 

The expanded coverage policy is effective immediately, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.